Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03379519
Other study ID # N201602069
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2016
Est. completion date December 31, 2019

Study information

Verified date February 2020
Source Ministry of Science and Technology, Taiwan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study sought to investigate the changes in attention in older adults with mild cognitive impairment after Multi-domain Attention Training .


Description:

This double-blind randomized controlled study has a 2-arm parallel group design. All subjects will be randomized by the block randomization, into intervention group (Multi-domain Attention Training, MAT), or active control group (Passive information activities, PIA). Training sessions of the MAT group are 45 minutes/day, 3 days/week, for 12 weeks (36 sessions each). The training of PIA group is the same as MAT group. The investigators constructed a rigorous MAT program adhering to the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines. The investigators expect to determine the improvement in attention function of older adults with mild cognitive impairment after using the MAT program.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 31, 2019
Est. primary completion date May 31, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Participants must endorse at least two items from a list of frequent subjective memory complaints by patient and/or an informant

- Objective memory impairment on neuropsychological tests of memory 1.5 SD or more below age/education norms

- Clinical neurologic examination by the Mini-Mental State Examination (MMSE) score of 24 or higher

- No impairment in personal activities of daily living (P-ADL) as determined by clinical interview with participant and family

Exclusion Criteria:

- The clinical diagnosis of dementia was based on the DSM-IV-TR

- Active in another cognitive or memory-related training in the past year

- Comorbid medical conditions that would predispose them to imminent functional decline or cognitive impairment

- A diagnosis of major neurological or psychiatric illness history and/or behavioral problems that would sufficiently impair performance to make participation impossible

- Severe losses in vision, hearing, or communicative ability

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Multi-domain Attention Training (MAT)
The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
Passive information activities (PIA)
The active control group (Passive information activities) training content included reading online e-books and playing online games.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ministry of Science and Technology, Taiwan

Outcome

Type Measure Description Time frame Safety issue
Primary Change in attention as measured by the Digit Span Task (DS). The primary outcome indicators is executive attention assessed by the Digit Span Task (DS). Change from baseline in executive attention at Immediate post-test, 3 months, 6 months after intervention.
Secondary Change in attention as measured by the Trail Making Test (TMT). The secondary outcome indicator is spatial orienting attention evaluated by the Trail Making Test. Change from baseline in spatial orienting attention at Immediate post-test, 3 months, 6 months after intervention.
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A